摘要
目的:对服用阿托伐他汀钙片的冠心病患者体内的hs-CRP水平变化进行研究.方法:将2011年1月-2014年9月笔者所在医院收治的200例冠心病患者,随机分为治疗组和对照组,每组100例。对照组采用常规方法治疗,治疗组加入阿托伐他汀钙片,治疗两个月后,检测两组用药前和用药后体内hs-CRP的水平。结果:两组用药后的hs-CRP水平均低于用药前(P<0.05),治疗前两组患者hs-CRP水平比较,差异无统计学意义(P>0.05),治疗后,治疗组hs-CRP水平高于对照组(P<0.05),治疗组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:阿托伐他汀钙片可以降低冠心病患者体内的hs-CRP水平,且能够提高药物的治疗效果。
Objective： To study the changes of hs-CRP levels in patients with coronary heart disease after take oral C Atorvastatin Calcium Tablets.Method： 200 patients with coronary heart disease in our hospital from January 2011 to September 2014 were randomly divided into the treatment group and the control group, 100 cases in each group.The control group was given conventional therapy, the t^atment group based on the control group added the Atorvastatin Calcium Tablets, after two months of treatment, the hs-CRP levels of the two groups were detected before and after medication.Result： After treatment, the hs-CRP levels of the two groups were lower than those before treatment（P〈0.05） before treatment, the hs-CRP levels of the two groups were compared, there was no statistically significant difference（P〉0.05）; after treatment, the hs-CRP level of the treatment group was higher than that in control group（P〈0.05）.The Adverse reaction rate of the treatment group was lower than that in control group, the difference was statistically significant（P〈0.05）.Conclusion： Atorvastatin Calcium Tablets can reduce the high sensitive C-reactive protein level in vivo in patients with coronary heart disease, and can improve the therapeutic effect of drugs.
出处
《中外医学研究》
2015年第32期24-25,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
冠心病
阿托伐他汀钙片
超敏C-反应蛋白
Coronary heart disease
Atorvastatin calcium tablets
High sensitivity C-reactive protein
